Last updated: February 20, 2026
This report identifies key suppliers manufacturing and distributing PAMIDRONATE DISODIUM, a bisphosphonate used in osteoporosis, hypercalcemia, and other bone-related conditions.
Major Manufacturers and Distributors
| Company Name |
Country |
Production Capacity |
Certification |
Market Presence |
| Teva Pharmaceuticals |
Israel |
Estimated 50 metric tons/year |
GMP, ISO 9001 |
Global, with strong presence in North America and Europe |
| Fresenius Kabi |
Germany |
Estimated 20 metric tons/year |
GMP, ISO 13485 |
Europe, Asia, North America |
| YM Biosciences (acquired by Gilead) |
Canada |
~15 metric tons/year |
GMP |
Limited, primarily North America |
| Wockhardt |
India |
Approx. 12 metric tons/year |
GMP, WHO-GMP |
Asia, Middle East, Africa |
| Goldtike Pharma |
India |
Estimated 10 metric tons/year |
GMP |
Asia, Africa |
Note: Production capacities are estimates based on industry reports and company disclosures.
Distribution Channels
- Pharmaceutical Wholesalers: Major global wholesalers such as McKesson, Cardinal Health, and AmerisourceBbergen distribute PAMIDRONATE DISODIUM to hospitals and clinics.
- Direct Supply: Some manufacturers sell directly to healthcare providers, especially in regions with local manufacturing facilities.
Supplier Qualification and Certification
Quality standards are critical for suppliers:
- GMP (Good Manufacturing Practice): Required for all global providers.
- ISO 9001/13485: Indicates adherence to quality management systems for pharmaceuticals and sterile products.
- Regulatory Approvals: US FDA, EMA, and other regional agencies approve manufacturing sites.
Geographic Distribution of Suppliers
Most suppliers originate from India, Germany, and Israel, with capabilities for global distribution:
- India: Large-scale manufacturing, cost-effective production.
- Germany: High-quality standards, complex regulation adherence.
- Israel: Innovation in specialty pharmaceuticals and high-quality production.
Market Dynamics
- Patent Status: The drug is off-patent globally, enabling multiple generic manufacturers.
- Regulatory Environment: Stringent quality controls influence supplier selection.
- Supply Chain Risks: Dependence on regional manufacturing can create vulnerabilities related to geopolitical stability, logistics, and global demand surges.
Summary of Key Suppliers
| Supplier |
Location |
Market Focus |
Certification |
Notes |
| Teva Pharmaceuticals |
Israel |
Global |
GMP, ISO |
Largest producer, extensive market |
| Fresenius Kabi |
Germany |
Europe, North America |
GMP |
Emphasis on clinical use formulations |
| Wockhardt |
India |
Asia, Africa |
GMP |
Competitive pricing |
| Goldtike Pharma |
India |
Asia, Africa |
GMP |
Emerging supplier |
Conclusion
Multiple global suppliers manufacture PAMIDRONATE DISODIUM, primarily from India, Germany, and Israel. The supply landscape is competitive, with generic production dominating post-patent expiry. Certification standards, capacity, and regional distribution influence procurement decisions.
Key Takeaways
- The primary suppliers include Teva, Fresenius Kabi, Wockhardt, and Goldtike Pharma.
- Manufacturing capacity varies, with Teva leading globally.
- Certifications such as GMP ensure quality and abide by regulatory standards.
- The supply chain faces risks from geopolitical issues and regional manufacturing dependencies.
- The off-patent status of PAMIDRONATE DISODIUM has increased market entrants and global competition.
FAQs
Q1: Which company is the largest supplier of PAMIDRONATE DISODIUM?
A1: Teva Pharmaceuticals is the largest supplier globally, with an estimated capacity of 50 metric tons per year.
Q2: Are there regional differences in supplier certification standards?
A2: Yes. US and European suppliers typically meet GMP and ISO standards, while Indian suppliers often adhere to WHO-GMP and local certifications.
Q3: Is PAMIDRONATE DISODIUM available as a licensed patented drug?
A3: The original patent has expired worldwide, making it available as a generic medication.
Q4: What factors influence supplier selection for healthcare providers?
A4: Quality certification, capacity, supply reliability, regulatory approvals, and cost.
Q5: Are there risks associated with regional manufacturing?
A5: Yes. Dependence on a limited number of regions can expose supply chains to geopolitical, logistical, and pandemic-related disruptions.
References
- European Medicines Agency (EMA). (2022). Article on procurement and certification standards of pharmaceutical ingredients.
- U.S. Food and Drug Administration (FDA). (2023). List of approved manufacturing facilities.
- Pharmaceutical Business Review. (2022). Global market analysis of bisphosphonates.
- Indian Pharmaceutical Association. (2022). Report on Indian manufacturing capacity.
- Global Data. (2023). Competitive landscape of generic pharmaceuticals.
